Related Experiment Video
Updated: Jun 17, 2026
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer
Marija Pastorcic-Grgic1, Bozena Sarcevic, Danijel Dosen
1Department of Head and Neck Surgery, University Hospital for Tumors, Zagreb, Croatia. marija_pastgrgic@yahoo.com
Background:
The prognostic value of cancer testis antigens in pharyngeal cancer is understudied.
Methods:
We recruited 90 patients who were treated for pharyngeal cancer. Monoclonal antibodies 57B and B9.8.1.1 were used for detection of MAGE-A and NY-ESO-1 genes.
Results:
MAGE-A and NY-ESO-1 gene products were detectable in 70.0% and 33.3% of pharyngeal tumors, respectively. No correlation was established between MAGE-A and NY-ESO-1 expression and TNM staging at presentation. Survival analysis showed a trend toward a shorter 5-year disease-free survival in the group of patients with MAGE-A-positive tumors (log-rank test, p = .122). In contrast, a trend toward a prolonged 5-year disease-free survival was observed in the group of patients with NY-ESO-1-positive tumors (log-rank test, p = .219).
Conclusion:
In a large population of patients with pharyngeal cancer and available 5-year survival data, prognosis tended to be poorer with MAGE-A expression and better with NY-ESO-1 expression, but the correlations did not reach statistical significance.